The combined company will be headquartered in Dublin, Ireland
News
GSK’s COVID-19 antibody shows potential in older patients
Investigational treatment did not show statistical significance in all age groups
NICE recommends routine funding for Novartis’ Kisqali
Drug recommended as a second-line treatment for certain advanced breast cancers
PharmaTimes are excited to announce the launch of CROY 2021
The prestigious Clinical Researcher of the Year – The Americas has now opened its doors for entry, continuing the successes of the 10th anniversary last year.
Pfizer’s tick-borne encephalitis vaccine gets US priority review
Prescription drug user fee act (PDUFA) action date anticipated for August 2021
Novo Nordisk invests in facility expansion at production site in Denmark
Production site in Måløv, Denmark manufactures products for oral diabetes treatment Rybelsus
Moderna sends South Africa variant-specific vaccine for clinical study
Modified vaccine candidate shipped to the US National Institutes of Health (NIH)
NHS Commercial Framework provides ‘welcome clarity’, says ABPI
The framework sets out the NHS’ approach to commercial activity in relation branded medicines
Ocugen’s inherited retinal disease gene therapy OCU400 wins orphan status
Orphan designation granted for the treatment of retinitis pigmentosa and Leber Congenital amaurosis
Sanofi partners with SIRION to improve AAV capsids for gene therapy treatments
Sanofi and SIRION will combine their technology platforms to develop next-generation AAV vectors
Parkinson’s UK creates Vivifi Biotech to research ‘promising’ experimental treatment
Biotech company will be dedicated to accelerating development of potential treatment
NHS England to trial at-home HPV testing kits
Over 31,000 women in London to be offered the at-home tests
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
UK sees a 20% growth in the number of advanced therapy trials, report finds
Cell and Gene Therapy Catapult report also found a surge in the number of commercially sponsored trials
MHRA approves Seagen’s Tukysa for HER2-positive breast cancer
Drug approved in a combination regimen for advanced breast cancer patients
